New article online!

We have a new publication relating to our work on the exposure-response relationships for efficacy and safety for mosunetuzumab, a T-cell engaging bispecific antibody targeting CD20xCD3 and approved for the treatment of relapsed/refractory follicular lymphoma.

Li CC, Bender B, Wilkins J, Li F, Turner DC, Wang B, et al. A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics [Online ahead of publication]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.3445